)
Visual
test
Gubra
Gubra (GUBRA) investor relations material
Gubra Investor presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Investor presentation summary18 Dec, 2025
Strategic highlights and partnerships
Out-licensed ABBV-295 (Amylin) to AbbVie in a USD 2.2 billion deal, including USD 350 million upfront payment.
Advanced first-in-class triple agonist BI 3034701 into mid-stage clinical development with Boehringer Ingelheim.
Entered collaboration with Camurus to develop long-acting PTH therapy for hypoparathyroidism.
UCN2 program to enter clinical trials in H1 2026, focusing on muscle-preserving weight loss and cardiac benefits.
Expanding pipeline beyond obesity and leveraging AI-driven peptide discovery platform.
Financial performance and outlook
Achieved record-high revenue of DKK 2.4 billion in the first nine months of 2025, mainly from the AbbVie deal.
CRO segment revenue declined 5% year-over-year due to macroeconomic headwinds, but order pipeline shows improvement.
Total adjusted costs increased to DKK 182 million as multiple projects advanced in parallel.
CRO EBIT margin impacted by one-off CEO compensation; excluding this, Q3 margin reached 19%.
2025 guidance: CRO revenue expected 5-10% below 2024, with mid-term target of 10% annual growth.
R&D pipeline and clinical progress
Pipeline includes internal and partnered programs in obesity, narcolepsy, hypoparathyroidism, rare diseases, and women's health.
ABBV-295 Phase 1 showed well-tolerated safety profile, 11-day half-life, and up to 7.8% weight loss over six weeks.
BI 3034701 demonstrated favorable safety and efficacy, advancing to mid-stage clinical trials.
UCN2 preclinical data showed preservation of lean mass, reduction in fat mass, improved cardiac function, and favorable biomarker profile.
UCN2 clinical Phase 1 planned for H1 2026, with ongoing non-clinical toxicity studies.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebPROV
Q2 FY2026 net income rose 65% year-over-year, with higher margins and strong credit quality. - 6 FebNVDA
AI-driven digital twins and accelerated computing are set to revolutionize industrial design and manufacturing. - 6 FebCDP
2025 FFO/share rose 5.8% to $2.72, with strong leasing and investment; 2026 guidance signals more growth. - 6 FebPECO
2026 FFO per share growth guided at 5.5% with record occupancy and robust acquisitions. - 6 FebCRI
Q1 2025 saw record revenue, a return to profit, and major new contracts in space technology. - 6 FebCRINet loss widened to 7.5m PLN in H1 2024 as revenue fell and R&D costs remained high.
- 6 FebCRINet loss deepened on lower sales and higher costs, but major new contracts and restructuring are underway.
- 6 FebEMBASSY
Record revenue, NOI, and distributions highlight strong growth and robust segment performance. - 6 FebCRIRevenue fell and losses deepened, but ESA contracts and R&D projects drive future prospects.
- 6 FebTUPRS
Net income reached TRY 29.5 billion, with strong dividends and a robust net cash position.
Next Gubra earnings date
Q4 202527 Feb, 2026
Gubra
Next Gubra earnings date
Q4 202527 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Gubra A/S is a Denmark-based biotechnology company specializing in pre-clinical contract research services and peptide-based drug discovery. The company's focus areas include metabolic and fibrotic diseases. Gubra operates through two main business segments: CRO Services and Discovery & Partnerships. It leverages advanced technology platforms and utilizes automation, robotization, digitalization, artificial intelligence, and machine learning to enhance its research capabilities. The company is headquartered in Hørsholm, Denmark, and its shares are listed on the Nasdaq Copenhagen.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage